Literature DB >> 99034

Platinum nephrotoxicity.

N E Madias, J T Harrington.   

Abstract

Platinum coordination complexes have recently been introduced in cancer chemotherapy with considerable success. However, significant nephrotoxicity has emerged as a factor that limits the therapeutic usefulness of these compounds. In this article we review the available knowledge on platinum nephrotoxicity and its prevention that has been derived from both toxicologic studies in animals and clinical trials in human subjects.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 99034     DOI: 10.1016/0002-9343(78)90825-2

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  96 in total

1.  Plasma erythropoietin concentrations in patients receiving intensive platinum or nonplatinum chemotherapy.

Authors:  R Canaparo; F Casale; E Muntoni; G P Zara; C Della Pepa; E Berno; N Pons; G Fornari; M Eandi
Journal:  Br J Clin Pharmacol       Date:  2000-08       Impact factor: 4.335

Review 2.  Klotho as a potential biomarker and therapy for acute kidney injury.

Authors:  Ming-Chang Hu; Orson W Moe
Journal:  Nat Rev Nephrol       Date:  2012-06-05       Impact factor: 28.314

3.  Protection against cisplatin-induced lipid peroxidation and kidney damage by procaine in rats.

Authors:  L F Zhong; J G Zhang; M Zhang; S L Ma; Y X Xia
Journal:  Arch Toxicol       Date:  1990       Impact factor: 5.153

Review 4.  Cisplatin nephrotoxicity. A review.

Authors:  G Daugaard; U Abildgaard
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

5.  Risk and impact of delayed renal impairment in patients with locally advanced head and neck squamous cell carcinoma receiving chemoradiotherapy with cisplatin.

Authors:  Thana Patimarattananan; Arkom Nongnuch; Poompis Pattaranutaporn; Nattawut Unwanatham; Chuleeporn Jiarpinitnun; Nuttapong Ngamphaiboon
Journal:  Support Care Cancer       Date:  2020-06-10       Impact factor: 3.603

6.  Rationally designed oxaliplatin-nanoparticle for enhanced antitumor efficacy.

Authors:  Abhimanyu Paraskar; Shivani Soni; Bhaskar Roy; Anne-Laure Papa; Shiladitya Sengupta
Journal:  Nanotechnology       Date:  2012-02-24       Impact factor: 3.874

7.  Interaction between cisplatin and mesna in mice.

Authors:  R T Dorr; K Lagel
Journal:  J Cancer Res Clin Oncol       Date:  1989       Impact factor: 4.553

Review 8.  A Systematic Review of Strategies to Prevent Cisplatin-Induced Nephrotoxicity.

Authors:  Daniel J Crona; Aimee Faso; Tomohiro F Nishijima; Kathleen A McGraw; Matthew D Galsky; Matthew I Milowsky
Journal:  Oncologist       Date:  2017-04-24

9.  Attenuation of cisplatinum-induced nephrotoxicity in the rat by high salt diet, furosemide and acetazolamide.

Authors:  H T Heidemann; J F Gerkens; E K Jackson; R A Branch
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-04       Impact factor: 3.000

10.  Permeability change and brain tissue damage after intracarotid administration of cisplatin studied by double-tracer autoradiography in rats.

Authors:  S Sugimoto; Y L Yamamoto; S Nagahiro; M Diksic
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.